A Phase 2 interventional study of RIFAXIMIN VAGINAL TABLET 25 MG and RIFAXIMIN VAGINAL TABLET 100 MG in BACTERIAL VAGINOSIS, sponsored by Alfasigma S.p.A.. Terminated at 1 site in United States. Open to female participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2016-10-10.
Sponsored by Alfasigma S.p.A. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 82 studies in Vaginosis, Bacterial with a site in United States — 8 open to participants now, 8 under way, none of them phase 3. Vaginosis, Bacterial · United States.
Among the 82 studies in Vaginosis, Bacterial with a site in United States, this one is the 12th largest by enrollment of the 69 interventional ones that give a count, is one of 7 that started in 2015, is one of 14 in phase 2, and was the 42nd registered.
240 studies on the registry are indexed under Vaginosis, Bacterial; 39 are open to participants now.
Browse Vaginosis, Bacterial studies →8 of the 82 studies in Vaginosis, Bacterial with a site in United States are open now. Recruiting first, the newest first:
Nanopath, Inc · Sites in United States
Ages 18+ · Women only
Tulane University · Sites in United States
Ages 18+ · Healthy volunteers
Cern Corporation · Sites in United States
Ages 18+ · Women only
Queen's Medical Center · Sites in United States
Ages 18–54 · Women only · Healthy volunteers
Douglas Kwon · Sites in United States
Ages 18–50 · Women only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 23 Vaginosis, Bacterial studies recruiting now, 7 (30%) set no upper age limit and 16 (70%) stop at 75 or younger; 2 take children under 18; 9 take healthy volunteers.
This study: 18 Years to 50 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
82 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 19 · Phase 3 14 · Phase 4 10
First in 1999; this study’s year is marked. 7 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 392 is above the median of 100 across 203 interventional studies indexed under Vaginosis, Bacterial.
Median enrollment 81 across the 69 interventional studies, 519 across the 13 observational. Of the 66 that completed or were terminated, 30 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
30 of 82 have an industry lead sponsor. The 10 most frequent:
Alfasigma S.p.A. is the lead sponsor of 24 studies on the registry; 3 are open to participants now.
Alfasigma S.p.A. has 1 study filed under Vaginosis, Bacterial — fewer than ten, so there is no comparison to draw.
4 of the studies in Vaginosis, Bacterial with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07607470Nanopath, IncLarge Algorithm Setting and Validation Study | 2026-12 |
| NCT04046900Douglas KwonVaginal Microbiota Transplant | 2027-01-30 |
| NCT06472765Vaginal Biome ScienceVaginal Ecosystem and Network in the United States Study | 2027-05-15 |
| NCT01829204Texas Tech University Health Sciences CenterProspective Data Bank Creation to Study Vaginal Conditions | 2027-07 |
Add all 4 to your calendar (.ics) → With an account.
Among the 82 studies in Vaginosis, Bacterial with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
THE STUDY HAS BEEN DESIGNED TO COMPARE THE EFFICACY OF TWO DOSES (25 MG AND 100 MG) OF RIFAXIMIN VAGINAL TABLETS VERSUS PLACEBO IN SUBJECTS WITH BACTERIAL VAGINOSIS
THIS IS A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY PLANNING TO ENROL 626 SUBJECTS AFFECTED BY BACTERIAL VAGINOSIS.
PRIMARY ENDPOINT:
TO COMPARE THE EFFICACY OF TWO DOSES (25 MG AND 100 MG) OF RIFAXIMIN VAGINAL TABLETS VERSUS PLACEBO IN SUBJECTS WITH BACTERIAL VAGINOSIS
SECONDARY ENDPOINT:
TO COMPARE THE EFFICACY OF TWO DOSES (25 MG AND 100 MG) OF RIFAXIMIN VAGINAL TABLETS VERSUS METROGEL VAGINAL IN SUBJECTS WITH BACTERIAL VAGINOSIS.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Clinical diagnosis of bacterial vaginosis with Amsel's criteria (4 out of 4 fulfilled criteria):
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RIFAXIMIN VAGINAL TABLET 25 MG ADMINISTERED ONCE A DAY FOR 5 DAYS
Drug: RIFAXIMIN VAGINAL TABLET 25 MG
RIFAXIMIN VAGINAL TABLET 100 MG ADMINISTERED ONCE A DAY FOR 5 DAYS
Drug: RIFAXIMIN VAGINAL TABLET 100 MG
PLACEBO VAGINAL TABLET ADMINISTERED ONCE A DAY FOR 5 DAYS
Drug: PLACEBO VAGINAL TABLET
METROGEL VAGINAL ADMINISTERED ONCE A DAY FOR 5 DAYS
Drug: METROGEL VAGINAL
RIFAXIMIN VAGINAL TABLET 25 MG O.D./5 DAYS INTRAVAGINALLY
RIFAXIMIN VAGINAL TABLET 100 MG O.D./5 DAYS INTRAVAGINALLY
PLACEBO VAGINAL TABLET O.D./5 DAYS INTRAVAGINALLY
METROGEL VAGINAL O.D./5 DAYS INTRAVAGINALLY
CLINICAL CURE OF BACTERIAL VAGINOSIS
RESOLUTION OF 3 OUT OF 4 AMSEL'S CRITERIA, I.E. NORMAL PHYSIOLOGICAL DISCHARGE, NEGATIVE "WHIFF TEST", CLUE CELLS \>20%
Time frame: Day 22-30
BACTERIOLOGICAL CURE OF BACTERIAL VAGINOSIS
GRAM STAIN NUGENT SCORE \<4
Time frame: Day 22-30
THERAPEUTIC CURE OF BACTERIAL VAGINOSIS
AMSEL'S CRITERIA AND GRAM STAIN NUGENT (RESOLUTION OF 3 OUT OF 4 AMSEL'S CRITERIA AND NUGENT SCORE \<4)
Time frame: Day 22-30
MAINTENANCE OF CLINICAL CURE OF BACTERIAL VAGINOSIS
AMSEL'S CRITERIA (RESOLUTION OF 3 OUT OF 4 AMSEL'S CRITERIA)
Time frame: Day 61-70
MAINTENANCE OF BACTERIOLOGICAL CURE OF BACTERIAL VAGINOSIS
NUGENT SCORE \<4
Time frame: Day 61-70
MAINTENANCE OF THERAPEUTIC CURE OF BACTERIAL VAGINOSIS
AMSEL'S CRITERIA AND NUGENT SCORE (MAINTENANCE OF RESOLUTION OF 3 OUT OF 4 AMSEL'S CRITERIA AND NUGENT SCORE \<4)
Time frame: 60-69 DAYS AFTER THE FIRST DAY OF TREATMENT
NUMBER, INTENSITY AND TYPE OF ADVERSE EVENTS
The incidence of adverse events to be summarized by body system and MedDRA preferred term.
Time frame: Up to Day 70
LOCAL OBJECTIVE TOLERABILITY
Vaginal mucosa status in terms of erythema (score 0 to 3), edema (score 0 to 3), pethechial hemorrhages (absence/presence), ulcers (absence/presence)
Time frame: Day 22-30
LOCAL SUBJECTIVE TOLERABILITY
Grade (from 0 to 4) of vaginal itching, pain and burning
Time frame: Day 1 to Day 5
Plan to share: Undecided
No publications or documents are linked to this record.
The record gives a start of Apr 2015, a primary completion of Feb 2016 and a completion of Feb 2016. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Oct 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rifaximin